Download Citation
Article Source:
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
Wichert S,
Juliusson G,
Johansson Å,
Sonesson E,
Teige I,
et al.
(2017)
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.
PLOS ONE 12(2): e0171205.
https://doi.org/10.1371/journal.pone.0171205